Suppr超能文献

载有CXCL12的水凝胶(CLG):一种用于捕获和鉴定转移性循环肿瘤细胞(CTC)的新装置。

CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

作者信息

Portella Luigi, Bertolini Giulia, Guardascione Giuseppe, Di Febbraro Dario Guido, Ieranò Caterina, D'Alterio Crescenzo, Rea Giuseppina, Napolitano Maria, Santagata Sara, Trotta Anna Maria, Camerlingo Rosa, Scarpa Emilia, Cecere Sabrina Chiara, Ottaiano Alessandro, Palumbo Giuliano, Morabito Alessandro, Somma Teresa, De Rosa Giuseppe, Mayol Laura, Pacelli Roberto, Pignata Sandro, Scala Stefania

机构信息

Microenvironment Molecular Targets, Istituto Nazionale Tumori IRCCS - Fondazione G Pascale, Napoli, Italy.

Tumor Genomic Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

出版信息

Heliyon. 2024 Jul 31;10(15):e35524. doi: 10.1016/j.heliyon.2024.e35524. eCollection 2024 Aug 15.

Abstract

BACKGROUND

Circulating Tumor Cells (CTCs) represent a small, heterogeneous population that comprise the minority of cells able to develop metastasis. To trap and characterize CTCs with metastatic attitude, a CXCL12-loaded hyaluronic-gel (CLG) was developed. CXCR4+cells with invasive capability would infiltrate CLG.

METHODS

Human colon, renal, lung and ovarian cancer cells (HT29, A498, H460 and OVCAR8 respectively) were seeded on 150 μl Empty Gels (EG) or 300 ng/ml CXCL12 loaded gel (CLG) and allowed to infiltrate for 16 h. Gels were then digested and fixed with 2 % FA-HAse for human cancer cell enumeration or digested with HAse and cancer cells recovered. CLG-recovered cells migrated toward CXCL12 and were tested for colonies/spheres formation. Moreover, CXCR4, E-Cadherin and Vimentin expression was assessed through flow cytometry and RT-PCR. The clinical trial "TRAP4MET" recruited 48 metastatic/advanced cancer patients (8 OC, 8 LC, 8 GBM, 8 EC, 8 RCC and 8 EC). 10 cc whole blood were devoted to PBMCs extraction (7 cc) and ScreenCell™ filters (3 cc) CTCs evaluation. Ficoll-isolated patient's PBMCs were seeded over CLG and allowed to infiltrate for 16 h; gels were digested and fixed with 2 % FA-HAse, cells stained and DAPI+/CD45-/pan-CK + cells enumerated as CTCs.

RESULTS

Human cancer cells infiltrate CLG more efficiently than EG (CLG/EG ratio 1.25 for HT29/1.58 for A498/1.71 for H460 and 2.83 for OVCAR8). CLG-recovered HT29 cells display hybrid-mesenchymal features [low E-cadherin (40 %) and high vimentin (235 %) as compared to HT29], CXCR4 two-fold higher than HT29, efficiently migrate toward CXCL12 (two-fold higher than HT29) and developed higher number of colonies (171 ± 21 for HT29-CLG vs 131 ± 8 colonies for HT29)/larger spheres (spheroid area: 26561 ± 6142 μm for HT29-CLG vs 20297 ± 7238 for HT29). In TRAP4MET clinical trial, CLG-CTCs were isolated in 8/8 patients with OC, 6/8 with LC, 6/8 with CRC, 8/8 with EC, 8/8 with RCC cancer and 5/8 with GBM. Interestingly, in OC, LC and GBM, CLG isolated higher number of CTCs as compared to the conventional ScreenCell™ (CLG/SC ratio = 1.88 for OC, 2.47 for LC and 11.89 for GBM). Bland and Altman blot analysis and Passing and Bablok regression analysis showed concordance between the methodological approaches but indicate that SC and CLG are not superimposable suggesting that the two systems select cells with different features.

CONCLUSION

CLG might represent a new and easy tool to isolate invasive CTCs in multiple cancers such as OC, LC and GBM at today orphan of reliable methods to consistently detect CTCs.

摘要

背景

循环肿瘤细胞(CTC)是一小群异质性细胞,占能够发生转移的细胞中的少数。为了捕获并鉴定具有转移倾向的CTC,研发了一种负载CXCL12的透明质酸凝胶(CLG)。具有侵袭能力的CXCR4+细胞会浸润CLG。

方法

将人结肠、肾、肺和卵巢癌细胞(分别为HT29、A498、H460和OVCAR8)接种在150μl空凝胶(EG)或300ng/ml负载CXCL12的凝胶(CLG)上,使其浸润16小时。然后将凝胶消化,并用2%FA-HAse固定以进行人癌细胞计数,或用HAse消化并回收癌细胞。回收的CLG细胞向CXCL12迁移,并检测其形成集落/球体的能力。此外,通过流式细胞术和RT-PCR评估CXCR4、E-钙黏蛋白和波形蛋白的表达。“TRAP4MET”临床试验招募了48名转移性/晚期癌症患者(8例卵巢癌、8例肺癌、8例胶质母细胞瘤、8例子宫内膜癌、8例肾细胞癌和8例结直肠癌)。10cc全血用于提取外周血单核细胞(PBMC,7cc)和使用ScreenCell™过滤器评估CTC(3cc)。将经Ficoll分离的患者PBMC接种在CLG上,使其浸润16小时;将凝胶消化,并用2%FA-HAse固定,对细胞进行染色,并将DAPI+/CD45-/泛细胞角蛋白+细胞计为CTC。

结果

人癌细胞浸润CLG的效率高于EG(HT29的CLG/EG比值为1.25,A498为1.58,H460为1.71,OVCAR8为2.83)。回收的CLG HT29细胞表现出混合间充质特征[与HT29相比,E-钙黏蛋白低(40%)而波形蛋白高(235%)],CXCR4比HT29高两倍,能高效地向CXCL12迁移(比HT29高两倍),并形成更多数量的集落(HT29-CLG为171±21个集落,而HT29为131±8个集落)/更大的球体(球体面积:HT29-CLG为26561±6142μm²,而HT29为20297±7238μm²)。在TRAP4MET临床试验中,8/8例卵巢癌患者、6/8例肺癌患者、6/8例结直肠癌患者、8/8例子宫内膜癌患者、8/8例肾细胞癌患者和5/8例胶质母细胞瘤患者中分离出了CLG-CTC。有趣的是,在卵巢癌、肺癌和胶质母细胞瘤中,与传统的ScreenCell™相比,CLG分离出的CTC数量更多(卵巢癌的CLG/SC比值为1.88,肺癌为2.47,胶质母细胞瘤为11.89)。Bland和Altman印迹分析以及Passing和Bablok回归分析表明两种方法具有一致性,但表明SC和CLG不可叠加,这表明这两种系统选择的是具有不同特征的细胞。

结论

在目前缺乏可靠方法持续检测CTC的情况下,CLG可能是一种用于分离多种癌症(如卵巢癌、肺癌和胶质母细胞瘤)中侵袭性CTC细胞的新型简便工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0679/11336720/3385b2ff19f0/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验